Ligand to Participate in September Investor Conferences
Rhea-AI Summary
Ligand Pharmaceuticals (Nasdaq: LGND) announced its participation in two upcoming investor conferences in September 2025. CEO Todd Davis and CFO Tavo Espinoza will attend the Citi 20th Annual BioPharma Conference in Boston on September 3, participating in a fireside chat at 11:15 a.m. ET. The management team will also present at the H.C. Wainwright 27th Annual Global Investment Conference in New York on September 9 at 1:00 p.m. ET.
During both conferences, management will be available for one-on-one meetings with investors and attendees through their respective conference representatives.
Positive
- None.
Negative
- None.
JUPITER, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcoming investor conferences:
- Citi 20th Annual BioPharma Conference (Boston): Management will participate in a fireside chat on September 3, 2025 at 11:15 a.m. ET.
- H.C. Wainwright 27th Annual Global Investment Conference (New York): Management will present on September 9, 2025 at 1:00 p.m. ET.
Ligand management is scheduled to host one-on-one meetings with investors and attendees during these conferences. Investors interested in arranging one-on-one meetings should contact their Citi or H.C. Wainwright representative.
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing our technology to help partners discover and develop medicines. We partner with other pharmaceutical companies to attempt to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate our revenue. We operate two infrastructure-light royalty generating technology IP platform technologies. Our Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Our NITRICIL™ platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a broad range of indications. We have established multiple alliances, licenses and other business relationships with the world’s leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences and Baxter International. For more information, please visit www.ligand.com. Follow Ligand on X and LinkedIn.
We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts.
Contacts
Investors:
Melanie Herman
investors@ligand.com
(858) 550-7761
Media:
Kellie Walsh
media@ligand.com
(914) 315-6072
FAQ
When is Ligand (LGND) presenting at the Citi BioPharma Conference 2025?
What time is Ligand's presentation at the H.C. Wainwright Conference 2025?
Who will represent Ligand (LGND) at the September 2025 investor conferences?
How can investors schedule meetings with Ligand management at these conferences?
